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Abstract: 
Fusion genes are hallmarks of various cancer types and important determinants for diagnosis, 
prognosis and treatment possibilities. The promiscuity of fusion genes with respect to partner 
choice and exact breakpoint-positions restricts their detection in the diagnostic setting, even 
for known and recurrent fusion gene configurations. To accurately identify these gene fusions 
in an unbiased manner, we developed FUDGE: a FUsion gene Detection assay from Gene 
Enrichment. FUDGE couples target-selected and strand-specific CRISPR/Cas9 activity for 
enrichment and detection of fusion gene drivers (e.g. BRAF, EWSR1, KMT2A/MLL) - without 
prior knowledge of fusion partner or breakpoint-location - to long-read Nanopore sequencing. 
FUDGE encompasses a dedicated bioinformatics approach (NanoFG) to detect fusion genes 
from Nanopore sequencing data. Our strategy is flexible with respect to target choice and 
enables multiplexed enrichment for simultaneous analysis of several genes in multiple 
samples in a single sequencing run. We observe on average a 508 fold on-target enrichment 
and identify fusion breakpoints at nucleotide resolution - all within two days. We demonstrate 
that FUDGE effectively identifies fusion genes in cancer cell lines, tumor samples and on 
whole genome amplified DNA irrespective of partner gene or breakpoint-position in 100% of 
cases. Furthermore, we show that FUDGE is superior to routine diagnostic methods for fusion 
gene detection. In summary, we have developed a rapid and versatile fusion gene detection 
assay, providing an unparalleled opportunity for pan-cancer detection of fusion genes in 
routine diagnostics.  
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Introduction: 
Fusion genes are hallmarks of many human cancers. Recent studies suggest that up to 16% 
of cancers are driven by a fusion gene1. Some cancer types, such as prostate cancer or 
chronic myeloid leukemia, are characterized by a specific fusion gene (TMPRSS2-ERG and 
BCR-ABL1 respectively), whereas other cancer types do not show such clear associations 1,2. 
Most fusion genes are highly variable with respect to fusion gene configurations and exact 
breakpoint-locations. Often, one gene is a recurrent fusion partner (e.g. KMT2A/MLL, ALK) 
which exhibits a tissue-specific pattern3. However, these genes can fuse to a multitude of 
partners to obtain their oncogenic potential. One striking example is KMT2A, formerly known 
as MLL, which is a prominent fusion partner in pediatric acute myeloid leukemia (AML) and 
the predominant fusion partner in acute lymphocytic leukemia (ALL) diagnosed in infants (i.e. 
children <1 year of age), and has been reported with more than 130 different gene 
configurations4,5. 
Whereas fusion detection is pathognomonic for some cancer types, it is a determinant of 
prognosis or treatment choices in other cancer types6,7. However, the high levels of variability 
in fusion gene configurations drastically limits diagnostic detection. Current diagnostic 
strategies include (break-apart) Fluorescence In Situ Hybridization (FISH) and reverse 
transcription quantitative polymerase chain reaction (RT-qPCR) assays, depending on the 
knowledge and breakpoint-variability of the fusion partner7. However, these assays are 
laborious and time-consuming and may not identify the fusion partner. Targeted next 
generation sequencing (NGS) assays overcome these limitations partially, but are 
accompanied with a longer turnaround-time, increased costs and bioinformatic challenges.  
Recent long-read sequencing technologies such as Oxford Nanopore Technology (ONT) 
sequencing have proven immensely helpful in elucidating structural variation in human 
genomes8. Furthermore, the real-time sequencing capabilities yield abundant opportunities for 
clinical applications. However, sequencing throughput from one Nanopore flow cell (2-5x 
genome coverage) is insufficient to elucidate the complete structural variation (SV) landscape 
of a genome9. ONT recently released a Cas9-based protocol for enrichment of specific 
genomic regions, which utilizes the upstream (5’) and downstream (3’) flanking sequences of 
the region of interest (ROI), to excise the latter and perform targeted sequencing10. Two 
publications have utilized this method to study methylation and structural variants10 as well as 
genome duplications11. With this technique, a median on-target coverage of 165x and 254x 
was achieved, respectively, offering a unique tool to sequence SVs such as fusion genes. 
However, this approach requires knowledge of both flanking sequences of the ROI, which 
again restricts its application to detection of only known fusion gene partner combinations. 
We here developed FUDGE (FUsion gene Detection assay from Gene Enrichment) as a fusion 
gene identification strategy to perform targeted enrichment of fusion genes and identify - 
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without prior knowledge - the unknown fusion partner and precise breakpoint by using long-
read, real-time ONT sequencing. Furthermore, we created and implemented a complementary 
bioinformatic tool, NanoFG, to detect fusion genes from long-read Nanopore sequencing data. 
Utilizing this approach, we are able to achieve an average on-target coverage of 67x - resulting 
in an average enrichment of 508x - and identify fusion gene partners from various cancer types 
(e.g. AML, Ewing Sarcoma, Colon) within 48 hours. Additionally, we offer strategies for low-
input DNA samples (10 ng) as well as multiplexing of samples and targets to minimize assay 
costs. Finally, we utilized this method on material in which routine diagnostic procedures were 
unable to detect the fusion partner, and identified the fusion partner within 2 days. 
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Results:  
Schematic overview of fusion gene detection assay 
We developed FUDGE to specifically enrich for fusion genes in which only one gene partner 
is known and for which the other fusion gene partner and/or breakpoint is unknown. To achieve 
this, genomic DNA is dephosphorylated as previously described10 and a crRNA flanking the 
suspected breakpoint region(s) is utilized to target Cas9 to a specific genomic loci where it 
creates a double-strand DNA break (Fig. 1A). The Cas9 protein stays predominantly bound 
to the PAM-distal side of the cut, therefore masking the phosphorylation side on this end, while 
exposing phosphorylated DNA on the PAM-proximal side of the cut (Fig.1B). This 
phosphorylated DNA, following dA-tailing, creates a specific contact-point that can be used to 
anneal the ONT-specific sequencing adaptors - specifically to this region only. To achieve 
directionality, the crRNAs are designed in a strand-directed manner to specifically direct reads 
up- or downstream of the crRNA sequence - effectively sequencing into the suspected 5’ or 3’ 
fusion partner (Fig.1B, Methods, and Suppl. Fig.1). Thereafter, the enriched libraries are 
sequenced on one ONT flow cell. To robustly detect fusion genes from low coverage 
Nanopore sequencing data, we developed a bioinformatic tool, NanoFG, which reports fusion 
partners, exact breakpoint-locations, the breakpoint-sequence and primers for validation 
purposes (Fig. 1C). 
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Figure 1: Schematic overview of FUDGE 
(A) Genomic DNA sample is dephosphorylated and crRNA-guided target-specific double-
stranded cuts are introduced through Cas9. (B) Phosphorylation-sites are exposed through 
the double-strand breaks; however, Cas9 remains bound to the PAM-distal side of the cut and 
blocks phosphorylation of the DNA on this side. DNA-ends are dA-tailed and adaptors are 
ligated only to phosphorylated DNA-ends proximal to the PAM sequence. Sequencing 
direction is dictated by the adaptors, towards the unknown sequence. (C) Targeted libraries 
are loaded and sequenced on one ONT flow cell. NanoFG is run on the Nanopore sequencing 
data, extracts fusion-spanning reads, detects fusion genes and provides exact fusion gene 
configuration, breakpoint-location, breakpoint-sequence and fusion-spanning primer 
sequences.  
 
Genomic enrichment and directed sequencing with single-edge Cas9 targeting  
To test the ability of the fusion gene detection assay to generate sufficient enrichment and to 
direct reads in the desired direction, we applied FUDGE to genomic DNA from a male healthy 
donor. As a proof-of-principle we designed crRNAs for a panel of recurrent fusion partner 
genes (BRAF, EWSR1, and SS18) in a strand-specific manner. We performed two separate 
library preparations (PP1 and PP2) and targeted two different exons for each of the three 
genomic loci per library (Fig. 2A and Suppl. Table 1). As a positive control, we targeted two 
genomic loci (C9orf72 and FMR1) for which we previously performed targeted sequencing, 
and used two crRNAs flanking the ROI and with each targeting one of the two different strands 
(Fig. 2A and Suppl. Table 1). After the sample processing, libraries of PP1 and PP2 were 
pooled and sequenced a single flow cell. Sequencing resulted in a throughput of 1.665 Gbs 
which corresponds to a mean genome coverage  of 0.5x (Suppl. Table 1). For the loci where 
only one strand of the genome was targeted, on average 89% of the reads sequenced in the 
anticipated 5’ or 3’ direction (Fig. 2B-D and Suppl. Fig. 2A-E). The mean target-locus 
coverage (10 kb to both sides of the cut-position) was 87x (BRAF) (Fig. 2B), 96x (EWSR1) 
(Fig. 2C), 93x (SS18) (Fig. 2D), 71x (C9orf72) (Fig. 2E), and 24x (FMR1) (Fig. 2F). The 
average read-length was 9.9kb (Fig. 2G and Suppl. Table 1) and on average 116 reads 
crossed the most common fusion breakpoint-locations (Fig. 2B-D and Suppl. Table 1), 
proving the applicability of this assay to detect fusion genes irrespective of breakpoint-position.  
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 Figure 2: Cas9 enrichment across genomic loci 
(A) Cas9-introduced cuts targeting different genomic regions for crRNA pool PP1 and PP2. 
Boxes and numbers represent exons. Cut-positions are shown by scissors, PAM sequence 
indicates the directionality of crRNA design and arrows show the anticipated sequencing 
direction. (B-E) Coverage plots showing on-target coverage across multiple genomic loci. 
Dotted lines (green) indicate the crRNA-directed Cas9 cleavage positions and arrows indicate 
the directionality of reads created from the specific crRNA design. Red areas highlight the 
most common breakpoint-locations per gene. (F) The read-length distribution for the 
sequencing run. The dashed line indicates the mean read-length.  
 
Identification of gene fusions in cancer cell lines 
To test that FUDGE identifies fusion genes independent of targeted gene or breakpoint-
location, we applied this technique to three fusion-positive cancer cell lines in which the fusion 
configuration was previously identified. The Ewing sarcoma cell lines A457312 and CHP-10013 
harbour the EWSR1-FLI1 fusion gene and the synovial sarcoma HS-SYII cell line contains a 
SS18-SSX1 fusion14. We targeted three loci per sample (BRAF Exon 10, EWS Exon 7, SS18 
Exon 9) and sequenced the samples on one flow cell each (Suppl. Table 1). This produced a 
mean genome coverage of 0.24x (A4573), 0.14x (CHP-100) and 0.015x (HS-SYII) (Fig. 3A). 
We observed 13x (A4573), 15x (CHP-100) and 4x (HS-SYII) target-locus coverage (10 kb to 
both sides of the cut-position) and a sharp increase to 81x (A4573), 66x (CHP-100) and 11x 
(HS-SYII) on-target coverage (cut to breakpoint) due to the achieved directionality (Fig. 3A 
and Suppl. Fig.1). This relates to an overall on-target fold-enrichment of 342x (A4573), 443x 
(CHP-100) and 735x (HS-SYII) (Fig. 3B; Fig 3C-E). To easily identify fusion-spanning reads 
from Nanopore data, we developed NanoFG15. NanoFG is an amendment to NanoSV8 that 
calls fusion genes from Nanopore sequencing data and reports the exact breakpoint-location, 
breakpoint-sequence and breakpoint-spanning primers for each gene fusion (Fig. 1). NanoFG 
identified the two EWSR1-FLI1 fusion genes with 26 (A4573) (Fig. 3A and 3C) and 18 (CHP-
100) (Fig. 3A and 3D) fusion-spanning reads which relates to a fusion-specific enrichment of 
109x and 121x, respectively (Fig. 3B). The two Ewing sarcoma cell lines harboured the same 
fusion gene, however, with different breakpoint-locations (Suppl. Fig. 3). These differences 
were readily detected by NanoFG and emphasizes the flexibility of this assay to identify 
fusions without knowledge of the exact breakpoint-positions. To uncover why NanoFG didn’t 
identify the SS18-SSX1 fusion gene, we manually investigated the candidate loci in the IGV 
Browser16. The sequencing of the HS-SYII cell line resulted in very little throughput and on-
target coverage (11x) (Fig. 3A). As a result, only one fusion-spanning read was produced, 
which is below the filtering cut-off for fusion-supporting reads set for NanoFG (requirement of 
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minimal two fusion-supporting reads). When adjusting the settings of NanoFG to one 
supporting read, the SS18-SSX fusion was called (Fig. 3A and 3E), however, lowering the 
threshold of fusion-supporting reads requires manual validation if the fusion status is unknown 
to exclude false-positives. Despite the low-throughput for the HS-SYII cell line, the assay 
resulted in a 68x fusion-specific fold-enrichment (Fig. 3B). This shows the ability of FUDGE 
to identify fusion genes irrespective of fusion partner or breakpoint-location from low-coverage 
Nanopore sequencing data.  
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Figure 3: Coverage and enrichment across fusion-positive cancer cell lines 
(A) Mean coverage and (B) enrichment across the genome, target-locus (10 kb to both sides 
of the cut-position), on-target  (cut to breakpoint) and across the fusion junction for the three 
cell lines A4573, CHP-100 and HS-SYII. (C) Coverage plots for the cell line A4573 for the two 
fusion partners EWSR1 (targeted) and FLI1. (D) Coverage plots for the cell line CHP-100 for 
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the two fusion partners EWSR1 (targeted) and FLI1. (C) Coverage plots for the cell line HS-
SYII for the two fusion partners SS18 (targeted) and SSX1. Dotted lines (green) indicate the 
crRNA-directed Cas9 cleavage positions and dashed lines (red) indicate breakpoint positions. 
Arrows indicate the directionality of reads created from the specific crRNA design. 
  
 
Detection of fusion genes from tumor material  
To validate that FUDGE identifies fusion genes from tumor material and without prior 
knowledge of the fusion partner, we applied the assay to three tumor samples with (un-)known 
fusion status. We tested DNA isolated from an Ewing sarcoma (ES1; fusion unknown), a 
rhabdomyosarcoma (RH; fusion known), and an AML (AML1; one fusion partner known) 
tumor. Rhabdomyosarcomas are characterized by breaks in the second intron of FOXO1 (104 
kb) which then fuses to either PAX3 or PAX717. Due to the large region within FOXO1 where 
the break can potentially occur, we chose to target the PAX3 and PAX7 genes instead to 
minimize the number of necessary crRNAs. Here, the most common breakpoint areas span 
an 18 kb and 32 kb region, respectively. Therefore, we designed sequential crRNAs to span 
the potential breakpoint regions of both genes (Suppl. Table. 1). For the AML sample, 
diagnostic efforts identified a KMT2A fusion through break-apart FISH; however, the fusion 
partner could not be identified. The KMT2A gene is a frequent fusion partner in AML and ALL 
and shows two major breakpoint clusters 4 for both of which we designed crRNAs (Suppl. 
Table 1). We sequenced each tumor sample on a single flow cell and identified a EWSR1-
FLI1 (ES1) fusion (Suppl. Table. 1 and Suppl. Fig. 3 and 4), a reciprocal FOXO1-PAX3 (RH-
1) and PAX3-FOXO1 (RH-2) fusion (Fig. 4A), and a KMT2A-MLLT6 (AML1) fusion (Fig. 4B) 
with 7, 31, 8 and 25 fusion-spanning reads, respectively (Fig. 4C). The reciprocal FOXO1-
PAX3 fusion was validated by breakpoint PCR (Suppl. Fig. 5A). On-target enrichment was 
498x (ES1), 927x (RH) and 909x (AML1) and the fusion-specific enrichment was 237x (ES1), 
150x (RH-1), 65x (RH-2) and 124x (AML1) (Fig. 4D). This demonstrates the ability of FUDGE 
to detect known, unknown and reciprocal fusion genes from patient samples. Furthermore, we 
performed a retrospective time-course experiment to identify the necessary sequencing time 
to detect fusion-spanning reads (Fig. 4E). On-average, it took 3 hours of sequencing time to 
identify two fusion-spanning reads, highlighting the speed of our approach.  
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Figure 4: Fusion gene coverage and enrichment from tumor samples 
(A) Coverage plots for the RH tumor sample for the two fusion partners FOXO1 and PAX3. 
PAX3 was targeted with three sequential guides to span the 18kb possible breakpoint region. 
(B) Coverage plots for the AML1 tumor sample for the two fusion partners KMT2A (targeted) 
and MLLT6. (C)  Mean coverage and (D) mean enrichment across the genome, the target-
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locus (10 kb to both sides of the cut-position), on-target  (from cut to breakpoint) and across 
the fusion junction for the tumor samples ES1, RH and AML1. (E) Time-course experiment on 
sequencing time to identify fusion-spanning reads.  
 
 
Fusion gene detection from low-input tumor material 
The amount of available tumour material is often a limiting factor for genomic analysis. To 
circumvent this problem, we tested if our pipeline was compatible with whole genome amplified 
(WGA) material. Therefore, we sequenced two colon cancer samples (C1 and C2), known to 
harbor BRAF fusions (AGAP3-BRAF and TRIM24-BRAF, respectively)18. We performed WGA 
on 10 ng starting material and subjected 1 ug of WGA-DNA to the enrichment protocol. 
Genome coverage (Fig. 5A) and read-length were comparable to previous experiments 
(Suppl. Table 1). NanoFG detected the the AGAP3-BRAF fusion with one fusion-spanning 
read (Fig. 5A-C) and the TRIM24-BRAF fusion with 10 fusion-spanning reads (Fig. 5A-B, 5D). 
Of note, WGA introduced unwanted structural variation leading to an increased number fusion 
gene predictions. Fusion genes identified by NanoFG which were not targeted within our assay 
are very likely to be false-positives. To validate the two BRAF fusion genes, we utilized the 
exact breakpoint-locations provided by NanoFG and performed breakpoint-spanning PCR on 
the non-amplified tumor DNA (Suppl. Fig. 5B). This demonstrates the power of long-read 
sequencing to accurately identify structural variants from WGA material. Additionally, for the 
BRAF fusions, the breakpoint junction locations were 6.5 kb apart (Fig. 5C-D and Suppl. Fig. 
3), highlighting the unbiased performance of our assay.  Hence, we show the applicability of 
our protocol to identify fusion genes from tumor biopsies, even with very limited input material.   
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Figure 5: Fusion gene detection from WGA tumour DNA 
(A) Mean coverage and (B) enrichment across the genome, target-locus (10 kb to both sides 
of the cut-position), on-target  (from cut to breakpoint)  and across the fusion junction for the 
whole genome amplified tumor material C1 and C2. (C) Coverage plots for the whole genome 
amplified tumor material C1 for the two fusion partners AGAP3 and BRAF (targeted). (D) 
Coverage plots for the whole genome amplified tumor material C2 for the two fusion partners 
TRIM24 and BRAF (targeted). Dotted lines (green) indicate the crRNA-directed Cas9 cleavage 
positions and dashed lines (red) indicate breakpoint positions. Arrows indicate the 
directionality of reads created from the specific crRNA design. 
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Multiplexing of fusion-positive cell lines  
Parallel identification and cost-reduction are key for diagnostic approaches. Therefore, we 
tested the feasibility to multiplex samples in one sequencing run. We obtained DNA from four 
KMT2A-fusion positive cell lines (ALLPO, KOPN8, ML2 and Monomac-1) with different fusion 
partners (MLLT1, MLLT2, MLLT3 and MLLT4). We used two crRNAs targeting both breakpoint 
clusters (Suppl. Table. 1) and produced separate libraries for each sample (Fig. 6A). The 
targeted libraries were pooled pre-sequencing without barcoding and run on a single flow cell. 
This multiplexing approach resulted in a genome coverage of 0.57x and average read-length 
of 9.2kb (Suppl. Table 1). NanoFG identified the four different fusion partners (Suppl. Fig. 
6A) and 6 different breakpoint-locations (Fig. 6B) Interestingly, two KMT2A-fusions (MLLT2 
and MLLT3) appeared to be reciprocal (Suppl. Fig. 6A and Suppl. Fig. 6B). The breakpoints 
within KMT2A spanned a region of 6 kb, and we identified breakpoints for reciprocal fusions 
to be location-independent (Fig. 6C). We utilized the breakpoint-spanning primers and tested 
all samples for the occurrence of all fusion genes (Fig. 6A). This approach easily deconvoluted 
the sample-of-origin of each fusion, therefore validating this multiplexing approach (Suppl. 
Fig. 7A). Of note, the Monomac-1 cell line (KMT2A-MLLT3) also exhibited a positive result for 
the KMT2A-MLLT1 fusion. This could be traced back to a contamination in the cultured cell 
line, highlighting the sensitivity of this assay to detect subclonal events. Furthermore, from the 
coverage plot we observed 26 reads within the MLLT4 fusion partner (Suppl. Fig. 6A) which 
were not explained by any of the NanoFG detected fusions. Upon manual investigation in the 
IGV browser, we identified one fusion, KMT2A-MLLT4, that had a more complex 
rearrangement which was not called by NanoFG (Suppl. Fig. 7B). In this case, a small 30 bp 
region of KMT2A was deleted, followed by a 185 bp inversion and the ultimate fusion to 
MLLT4. We again designed breakpoint-spanning primers and additionally performed Sanger-
sequencing on the amplicons and validated the occurrence and structure of the complex 
rearrangement (Suppl. Fig. 7B). As a result, with the use of only one Nanopore flow cell, we 
identified seven fusion genes from four samples with a collective on-target enrichment of 349x 
resulting in an average of 18 fusion-spanning reads (Fig. 6D). This shows the ability of our 
approach to multiplex samples with different fusion genes and breakpoint-positions and 
pinpoint the sample-of-origin by a simple PCR assay. 
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Figure 6: Multiplexing of fusion-positive samples with varying breakpoints and fusion partners 
(A) Schematic overview of the multiplexing approach. Samples are prepared and subjected to 
the Cas9-enrichment individually and pooled equally pre-sequencing. The library-pool is 
sequenced on a single ONT Flow Cell and NanoFG detected fusion genes and designed 
fusion-specific breakpoint primers. Original samples are subjected to breakpoint PCR to 
identify the sample-of-origin for each fusion gene. (B) Coverage plots for KMT2A (targeted). 
Dotted lines (green) indicate the crRNA-directed Cas9 cleavage positions and dashed lines 
(red) indicate breakpoint positions. Arrows indicate the directionality of reads created from the 
specific crRNA design. (C) Breakpoint locations within the KMT2A gene for the different 
identified fusion genes. Breaks cluster between Exon 8 and 12 and reciprocal fusion genes 
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are highlighted in the same color. (D) Mean enrichment across the target-locus (10kb to both 
sides of the cut-position), on-target (from cut to breakpoint) and across the fusion junctions.  
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Discussion 
Fusion genes are detrimental determinants for diagnosis, prognosis and treatment 
opportunities for various cancer types19. However, fusion gene detection by diagnostic 
approaches is limited to highly recurrent fusion gene configurations. We here developed 
FUDGE, a fusion gene detection assay from gene enrichment coupled to Nanopore 
sequencing, which enables rapid partner- and breakpoint-location independant fusion gene 
detection within 48 hours. 
Common diagnostic approaches for fusion gene detection range from targeted (qPCR) to 
semi-targeted (FISH) and unbiased (Whole Genome Sequencing (WGS); RNA-Seq) 
solutions7,19. All offer some benefit but are limited in accuracy, resolution, or turnaround-time. 
qPCR assays offer accurate information on the fusion partners present and the exact 
breakpoint location; however, due to the large variety of possible fusion partners and 
breakpoint-positions, only highly recurrent events can be investigated. FISH offers detection 
of one fusion partner, but is restricted to one gene per test and does not provide information 
on the fusion partner. WGS and RNA-Seq potentially detects all fusion genes present in a 
given sample; however, both are hampered by a high turn-around time and WGS can result 
in high false-positive rates. A combination of these techniques can be utilized for more specific 
characterization of fusion genes (i.e. FISH followed by qPCR), but at the cost of both time and 
money.  
With FUDGE we offer fast and unbiased fusion gene detection. We successfully identified 
fusion genes in 100% of the investigated samples independent of cancer type or fusion gene 
configuration and/or breakpoint-positions. We targeted five recurrent fusion partners and 
identified 16 unique fusion gene configurations, highlighting the complexity of fusion gene 
biology. In one case, KMT2A was identified as a fusion partner by break-apart FISH through 
diagnostic efforts; however, the fusion partner was undetectable. We applied FUDGE to the 
sample and identified MLLT6 as the fusion partner within 2 days (provided the crRNA was 
already designed and in-house). Furthermore, FUDGE also detects reciprocal fusion events 
without additional efforts. In the case of two BRAF fusion-positive samples, the breakpoint 
locations were > 6 kb apart from each other. Conventional methods such as qPCR would have 
not sufficed to span this large region of possible breakpoint-positions. We integrated an 
adaptation to the protocol to design sequential guides, offering the opportunity to span large 
regions of possible breakpoint-locations. For the FOXO1-PAX3 fusion, we spanned a >20kb 
region and identified the breakpoint 7,5 kb from the first targeted sequence, highlighting the 
versatility of FUDGE. 
With our assay, fusion detection is possible within 48 hours. Rapid identification of fusion 
genes is essential for tumor types where fusion genes are pathognomonic such as Ewing 
sarcoma or synovial sarcoma19,20. Hence, early detection allows for early definitive diagnosis 
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and treatment initiation. Furthermore, occurence of a specific fusion gene configuration can 
be a determinant of prognosis21. FUDGE identified all fusion gene configurations within 48 
hours, allowing ultrafast diagnosis and treatment initiation. Additionally we show that 3 hours 
of sequencing are sufficient to identify two fusion-spanning reads, offering the opportunity to 
reduce the assay time for urgent cases to less than a day.  
Intratumoral heterogeneity and tumor purity are likely to influence the lower detection limits of 
our assay. We set a cut-off of at least two fusion-spanning reads to reliably detect a fusion 
gene. For the samples HS-SYII and C1, sequencing throughput was very low, resulting in a 
low on-target coverage. Furthermore, the fusion breakpoints were approximately 6 kb and 9 
kb, respectively, from the targeted region, lowering the amount of reads in the breakpoint area. 
Here, the fusions were only detected with one fusion-spanning read each, requiring the 
manual validation of the fusion gene by breakpoint PCR. However, with incorporating a multi-
crRNA approach and increased efforts from ONT to improve sequencing throughput, FUDGE 
is expected to improve. Additionally, the latter would allow for higher capacities to multiplex 
samples, reducing costs of the assay further.  
Until now, we focused our assay on five recurrent fusion genes, however, expanding the assay 
to any gene of interest is possible. Furthermore, rapid detection of the exact breakpoint-
positions opens the doors to immediately trace fusion molecules within ctDNA from liquid 
biopsies and monitor treatment responses and minimal residual disease.  
In conclusion, FUDGE identifies fusion genes irrespective of fusion partner or breakpoint-
location from low-coverage Nanopore sequencing. With its requirement for only very little 
amount of tumour material, its ability to multiplex targets as well as samples and its rapid 
nature, FUDGE overcomes various limitations of current diagnostic assays. Therefore, 
FUDGE permits initiation of appropriate therapies and options for blood-based minimal 
residual disease testing within due time after patient presentation.  
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Material & Methods: 
 
Cell Lines and Culture 
Ewing sarcoma cell lines (A4573, CHP-100) and synovial sarcoma cell line (HS-SYII) were 
cultured in 5% CO2 in a humidified atmosphere at 37 °C in Dulbecco’s modified medium 
(DMEM) (Thermo Fisher) supplemented with 10 % fetal bovine serum (FBS) and antibiotics 
(100 U / ml penicillin and 100 μg / ml streptomycin). The absence of Mycoplasma sp. 
contamination was determined with a Lonza MycoAlert system.  
ALL cell lines ALL-PO and KOPN8 and AML cell lines ML2 and Monomac-1 were maintained 
as suspension cultures in RPMI-1640 medium (Invitrogen), supplemented with 10% or 20% 
fetal calf serum (FCS) and antibiotics.  
 
Patient material 
The healthy donor (PP) provided oral informed consent. The patients ES1 and RH had been 
registered and treated according to German trial protocols of the German Society of Pediatric 
Oncology and Hematology (GPOH). This study was conducted in accordance with the 
Declaration of Helsinki and Good Clinical Practice, and informed consent was obtained from 
all patients or their guardians. Collection and use of patient specimen was approved by the 
institutional review boards of Charité Universitätsmedizin Berlin. Specimen, clinical data were 
archived and made available by Charité-Universitätsmedizin Berlin. 
C1 and C2 were previously sequenced 18 and were kindly provided by Prof Ijzermans, Dept of 
Surgery,  Erasmus Medical Center Rotterdam, The Netherlands.  
AML1 was a kind gift from Prof. dr. C.M. Zwaan, Erasmus Medical Center – Sophia Children’s 
Hospital, Rotterdam, The Netherlands / Princess Maxima Center for Pediatric Oncology, 
Utrecht, The Netherlands. Informed consent is given by the patient or his/her parents or legal 
guardians, and all is performed in line with the declaration of Helsinki, and the Erasmus MC – 
Sophia Children’s Hospital approved the experiments. 
 
DNA-Isolations 
Genomic DNA from cultured cells (A4573, CHP-100 and HS-SYII) and tissue (ES1 and RH) 
was extracted by using the column-based NucleoSpin® Tissue DNA extraction kit (Macherey-
Nagel) following manufacturer's instructions. Sample quality control was performed using a 
4200 TapeStation System (Agilent), and DNA content was measured with a Qubit 3.0 
Fluorometer (Thermo Fisher). 
Genomic DNA from the ALL cell lines (ALLPO and KOPN8),  AML cell lines (ML2 and 
Monomac-1) and AML patient (AML1) was isolated by using the column-based Qiagen 
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DNeasy Blood & Tissue  DNA extraction kit (Qiagen) following the manufacturer's instructions 
and DNA content was measured with a Qubit 2.0 Fluorometer (Thermo Fisher). 
 
WGA 
For whole genome amplification (WGA), 10 ng starting material was amplified with the repli-g 
mini kit (Qiagen) according to the manufacturer's protocol. 
 
crRNA design 
Each potential gene fusion constituted a known fusion partner to be targeted with this 
enrichment technique, and an (un)known partner to be identified following subsequent 
sequencing. The known target fusion partners were designated as a 5’ or 3’ fusion partner, 
dependent upon known literature. Furthermore, the most common breakpoint locations were 
extracted from a literature search and the most distal breakpoint locations were noted as 
extreme borders of the targeted area. If the unknown fusion partner was the 5’ partner, crRNAs 
were designed as the sequence present on the minus strand of the gene (5’->3’) until the PAM 
sequence. If the unknown fusion partner was the 3’ partner, crRNAs were designed as the 
sequence present on the plus strand of the gene (5’->3’) until the PAM sequence (Suppl. Fig. 
1). Custom Alt-R®� crRNAs were designed with the Integrated DNA Technologies (IDT) custom 
gRNA design tool and chosen with maximum on-target and lowest off-target scores (IDT).  
 
Cas9-Enrichment and Nanopore Sequencing 
Cas9 enrichment was adapted from the ONT Cas9 enrichment protocol10. In brief, 
approximately 1 ug of genomic DNA or WGA-DNA (See Suppl. Table 1) was 
dephosphorylated with Quick calf intestinal phosphatase (NEB) and CutSmart Buffer (NEB) 
for 10 minutes at 37 ℃ and inactivated for 2 minutes at 80 ℃. crRNAs were resuspended in TE 
pH7.5 to 100 uM. For simultaneous targeting of multiple loci, crRNAs were pooled equimolarly 
to 100 uM. Ribonucleoprotein complexes (RNPs) were prepared by mixing 100 uM 
equimolarialy pooled crRNA pools with 100 uM tracrRNA (IDT) and duplex buffer (IDT), 
incubated for 5 minutes at 95 ℃ and thereafter cooled to room temperature. 10 uM RNPs were 
mixed with 62 uM HiFiCas9 (IDT) and 1x CutSMart buffer (NEB) and incubated at RT for 15 
minutes produce Cas9 RNPs. Dephosphorylated DNA sample and Cas9 RNPs were mixed 
with 10mM dATP and Taq polymerase (NEB) at 37 °C for 15 minutes and 72 °C for 5 minutes 
to facilitate cutting of the genomic DNA and dA-tailing. Adaptor ligation mix was prepared by 
mixing Ligation Buffer (SQK-LSK109, ONT), Next Quick T4 DNA Ligase (NEB) and Adaptor 
Mix (SQK-LSK109, ONT). The mix was carefully applied to the processed DNA sample without 
vortexing and incubated at room temperature for 25 minutes. DNA was washed and bound to 
beads by adding TE pH8.0 and 0.3 x volume AMPure XP beads (Agencourt) and incubated 
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for 10 minutes at room temperature. Fragments below 3 kb were washed away by washing 
the bead-bound solution twice with Long Fragment Buffer (SQK-LSK109, ONT). Enriched 
library was released from the beads with Elution Buffer (SQK-LSK109, ONT). Enriched library 
concentration was measured with the a Qubit Fluorometer 3.0 (Thermo Fisher). 
The library from one tumour sample was loaded onto one Flow Cell (R 9.4, ONT) according 
to the manufacturer's protocol. Sequencing was performed on a GridION X5 instrument (ONT) 
and basecalling was performed by Guppy (ONT). 
 
NanoFG 
NanoFG can be found in https://github.com/SdeBlank/NanoFG 
Mapping and SV detection 
Reads were mapped to the human reference genome version GRCHh37 by using minimap2 
(v. 2.6)22 with parameters: ‘-x map-ont -a’. The produced SAM file was compressed to bam 
format and indexed with samtools (v. 1.7)23. Next, structural variations were detected from the 
bam file. The user can choose either NanoSV (v. 1.2.4)8 with default parameters: 
‘min_mapq=12, depth_support=False, mapq_flag=48’ or Sniffles23 with default parameters: '-
s 2 -n -1 --genotype' to detect SVs. We here used NanoSV for all experiments (except 
multiplexing). For the samples C1 and HS-SYII, additional parameters: ‘cluster_count=1’ were 
used for NanoSV due to the low number of reads spanning the fusion. For the multiplexing 
experiment, the fraction of reads supporting the fusions was below the allele frequency cut-off 
in NanoSV. Therefore, the default Sniffles settings were used to detect 6 fusions. By default, 
all SVs that do not pass the built-in NanoSV or Sniffles filters are removed. Additionally, all 
insertions are also removed from the VCF.  
Selection of reads supporting possible fusions  
NanoFG selected candidate SVs that possibly form a fusion gene by annotating both ends of 
an SV with genes from the ENSEMBL database24. If both ends of the SV are positioned in 
different genes it was flagged as a possible fusion. Next, all the reads supporting the candidate 
SVs were extracted with samtools (v. 1.7)25 .  
Remapping and SV detection 
All reads extracted per candidate fusion gene were re-mapped using LAST26 with default 
settings for increased mapping accuracy. Then, NanoSV was used to accurately define the 
breakpoints in the remapped fusion candidates. NanoSV parameters ‘cluster_count=2, 
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depth_support=False’ were used to detect all present fusions. For C1 and HS-SYII, 
‘cluster_count=1’ was used as a parameter for NanoSV. 
 Checking and flagging fusions 
Additional information from the ENSEMBL database was gathered to produce an exact 
composition of the fusion gene. Only fusions that have the ability to produce a continuous 
transcript on the same strand were retained and additional flags were added to the sample to 
give extra indication if reported fusions are likely important or if some information from the 
ENSEMBL database is incomplete. 
Output generation and visualization 
All gathered ENSEMBL gene information was used to produce an overview of the detected 
fusions. This includes the genes involved, the exon or intron containing the breakpoint, the 
exact position of the fusion, the number of fusion supporting reads, involved CDS length of 
both fused genes and the final fused CDS length. The detected fusions were also reported in 
VCF format for further analysis. To give a better overview of detected fusions, NanoFG also 
produced a visual overview in PDF format. Apart from information on the genes, flags, position 
and fusion supporting reads it also included the locations of protein domains to provide quick 
insight into what domain are involved in the fusion. 
Primer design 
NanoFG automatically designed primers for fusion gene validation using primer37 with default 
settings, aiming for a 200-400 bp product. 
 
Minimal sequencing duration experiment 
To detect differences in fusion gene detection based upon sequencing duration, all fastqs 
were merged and all reads were sorted based on the time of sequencing. The earliest time 
was taken as the start of the sequencing run and subsequently reads were selected based on 
bins of 1, 2, 3, 4, 5, 6, 12, 18, 24, 30, 36, 42 and 48 hours after the first read had been 
sequenced. NanoFG was then run separately on every fastq by using default settings for every 
sample. Using this approach, the time points where at least 2 supporting reads of a fusion 
have been sequenced can be determined to define the minimal sequencing duration 
necessary for each sample to produce two fusion-spanning reads.  
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